article thumbnail

JPM24: Riding label expansions and launches, AZ plots course toward 'industry-leading growth' by 2030

Fierce Pharma

In AZ's push to reach industry-leading growth by 2030, confidence is key, chief financial officer Aradhana Sarin said at the J.P. Morgan Healthcare Conference. With a late-stage pipeline spanning more than 120 clinical trials and a firm grasp of five major disease areas, AstraZeneca appears confident heading into 2024. |

Leads 264
article thumbnail

What Will Value-Based Drug Pricing Look Like By 2030? Experts Share 4 Predictions

MedCity News

For example, one said that healthcare will be close to establishing a value-based formulary by 2030, and another said that longitudinal patient tracking will become a more important part the drug pricing process. Panelists at a recent pharmacy conference were optimistic about the future of value-based drug contracting.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Sorry, the Inflation Bill won’t lower healthcare costs

World of DTC Marketing

The Inflation Reduction Act’s health insurance subsidies and drug pricing reforms will improve health care affordability for Americans but won’t do a damn thing for our overall healthcare costs, which will keep rising. 1ne: A new analysis predicts that by 2030, 48.9% A staggering 85% of healthcare costs in the U.S.

article thumbnail

Monday Healthcare Headlines

World of DTC Marketing

The study reveals that by 2030 the ratio will decline sharply to 4 to 1 and by 2050, 3 to 1. The post Monday Healthcare Headlines appeared first on World of DTC Marketing.com. The rest were additional approvals of an existing drug or first approvals of a “me-too” drug that enters an existing class of treatment.

article thumbnail

Micro-robots, smart toilets, and 3D bioprinted organs: the future of healthcare

Pharmaceutical Technology

It is the year 2030. Your healthcare practitioner can access the sequencing results, and artificial intelligence (AI) and quantum computing will analyse these records and support the practitioner in making future clinical decisions. It is the year 2030.

article thumbnail

OSD contract manufacturing market valued at $54.7 billion by 2030

European Pharmaceutical Review

billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 During 2020, the COVID-19 pandemic depleted the healthcare sector’s revenue due to shortages in the workforce and major disturbance to the raw material supply chain. billion by 2030 appeared first on European Pharmaceutical Review.

article thumbnail

Value and potential of IoT and AI for chronic diseases treatment

PharmaVoice

A significant growth is predicted for both AI and IoT in healthcare. By 2030, the AI market is expected to reach $187.95 billion USD, while the IoT market is projected to climb even higher to $312.7 billion USD.